These shRNAs delivered by jetPEI-Hepatocyte, especially the combination of the anti-HBx shRNA pGenesil-siHBV4 and the anti-survivin shRNA pGenesil-siSurvivin, are promising therapeutics for potential application in the two stages of the detrimental disease – chronic HBV infection and its related HCC. The gene discussed is BIRC5; the disease is hepatocellular carcinoma.